Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 49 articles: HTML format Text format

Single Articles

January 2012
1. ALEXANDRE J , Brown C, Coeffic D, Raban N, et al
   CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
   Br J Cancer. 2012 Jan 12. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. COLEY HM , Safuwan NA, Chivers P, Papacharalbous E, et al
   The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
   Br J Cancer. 2012 Jan 10. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. BLANK MM , Wentzensen N, Murphy MA, Hollenbeck A, et al
   Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study.
   Br J Cancer. 2012 Jan 5. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
4. TAYLOR-HARDING B , Agadjanian H, Nassanian H, Kwon S, et al
   Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
   Br J Cancer. 2011 Dec 13. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. PARKIN DM
   15. Cancers attributable to reproductive factors in the UK in 2010.
   Br J Cancer. 2011;105 Suppl 2:S73-6.
   PubMed     Text format     Related articles   
   
   
   
   
6. PARKIN DM
   10. Cancers attributable to exposure to hormones in the UK in 2010.
   Br J Cancer. 2011;105 Suppl 2:S42-8.
   PubMed     Text format     Related articles   
   
   
   
   November 2011
7. GOEBEL G , Berger R, Strasak AM, Egle D, et al
   Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.
   Br J Cancer. 2011 Nov 22. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. MCMEEKIN S , Patel R, Verschraegen C, Celano P, et al
   Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.
   Br J Cancer. 2011 Nov 22. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
9. HOFSTETTER G , Berger A, Schuster E, Wolf A, et al
   Delta133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
   Br J Cancer. 2011 Oct 18. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. KAJIYAMA H , Shibata K, Mizuno M, Umezu T, et al
    Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery.
    Br J Cancer. 2011 Oct 4. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
11. LEE CK , Simes RJ, Brown C, Lord S, et al
    Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2011 Sep 13. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. TSILIDIS KK , Allen NE, Key TJ, Dossus L, et al
    Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition.
    Br J Cancer. 2011 Sep 13. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. BOCKELMAN C , Lassus H, Hemmes A, Leminen A, et al
    Prognostic role of CIP2A expression in serous ovarian cancer.
    Br J Cancer. 2011 Sep 6. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
14. RAJA FA , Griffin CL, Qian W, Hirte H, et al
    Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    Br J Cancer. 2011 Aug 30. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. ZANG RY , Harter P, Chi DS, Sehouli J, et al
    Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
    Br J Cancer. 2011 Aug 30. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. DHILLON PK , Yeole BB, Dikshit R, Kurkure AP, et al
    Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an age-period-cohort analysis.
    Br J Cancer. 2011 Aug 9. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
17. MAHDI H , Swensen RE, Hanna R, Kumar S, et al
    Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary.
    Br J Cancer. 2011 Jul 19. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. LEE CK , Gurney H, Brown C, Sorio R, et al
    Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. PEASLAND A , Wang LZ, Rowling E, Kyle S, et al
    Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
    Br J Cancer. 2011 Jul 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
20. LANGMAR Z , Nemeth M, Szekely B, Borgulya G, et al
    The performance of the risk of ovarian malignancy algorithm.
    Br J Cancer. 2011;105:185-6.
    PubMed     Text format     Related articles   
    
    
    
    
21. JULIN B , Wolk A, Akesson A
    Dietary cadmium exposure and risk of epithelial ovarian cancer in a prospective cohort of Swedish women.
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. VAN DER GUN BT , de Groote ML, Kazemier HG, Arendzen AJ, et al
    Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer.
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. SABATIER R , Finetti P, Bonensea J, Jacquemier J, et al
    A seven-gene prognostic model for platinum-treated ovarian carcinomas.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. CHALLBERG J , Ashcroft L, Lalloo F, Eckersley B, et al
    Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
25. CASTELLSAGUE X , Munoz N, Pitisuttithum P, Ferris D, et al
    End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
26. BRUNING-RICHARDSON A , Bond J, Alsiary R, Richardson J, et al
    ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. BERNATSKY S , Ramsey-Goldman R, Foulkes WD, Gordon C, et al
    Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. DUIKER EW , Meijer A, van der Bilt AR, Meersma GJ, et al
    Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
    Br J Cancer. 2011;104:1278-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
29. SHENG Q , Liu J
    The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
30. WALLIN A , Orsini N, Wolk A
    Red and processed meat consumption and risk of ovarian cancer: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. MAULAND KK , Trovik J, Wik E, Raeder MB, et al
    High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. COMAMALA M , Pinard M, Theriault C, Matte I, et al
    Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. VAN GORP T , Cadron I, Despierre E, Daemen A, et al
    HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
34. RETTENMAIER NB , Rettenmaier CR, Wojciechowski T, Abaid LN, et al
    The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
35. MERN DS , Hasskarl J, Burwinkel B
    Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
36. GLAYSHER S , Gabriel FG, Johnson P, Polak M, et al
    Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. HAUSLER SF , Keller A, Chandran PA, Ziegler K, et al
    Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
38. LEFFERS N , Fehrmann RS, Gooden MJ, Schulze UR, et al
    Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. RYAN MC , Kostner H, Gordon KA, Duniho S, et al
    Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. FALLOWFIELD L , Fleissig A, Barrett J, Menon U, et al
    Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21 715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
41. DELORD JP , Quideau S, Rochaix P, Caselles O, et al
    Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.
    Br J Cancer. 2010;103:61-72.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
42. RUSTIN GJ , Shreeves G, Nathan PD, Gaya A, et al
    A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
    Br J Cancer. 2010;102:1355-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
43. HU L , McArthur C, Jaffe RB
    Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. WHITE NM , Chow TF, Mejia-Guerrero S, Diamandis M, et al
    Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. TATE AR , Nicholson A, Cassell JA
    Are GPs under-investigating older patients presenting with symptoms of ovarian cancer? Observational study using General Practice Research Database.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
46. SEEBACHER V , Polterauer S, Grimm C, Husslein H, et al
    The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. LEE JM , Sarosy GA, Annunziata CM, Azad N, et al
    Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
    Br J Cancer. 2010;102:495-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
48. AL-ATTAR A , Gossage L, Fareed KR, Shehata M, et al
    Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. FALASCA M , Chiozzotto D, Godage HY, Mazzoletti M, et al
    A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
    Br J Cancer. 2010;102:104-14.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: